Pete Smith, Remix Therapeutics president and CEO
January 3, 2024 07:00 AM EST
Financing
Startups
Deals

Roche lines up RNA pact with Remix Ther­a­peu­tics, which al­so raised an­oth­er $60M

Kyle LaHucik

Senior Reporter

Roche said Wednes­day it will cre­ate new drugs with the help of RNA pro­cess­ing mod­u­la­tor Remix Ther­a­peu­tics in a deal that in­volves $30 mil­lion up­front …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

A service from the Financial Times